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Abstract
Context: The role of CNVs in male infertility is poorly defined, and only those linked to the Y chromosome have been the
object of extensive research. Although it has been predicted that the X chromosome is also enriched in spermatogenesis
genes, no clinically relevant gene mutations have been identified so far.
Objectives: In order to advance our understanding of the role of X-linked genetic factors in male infertility, we applied high
resolution X chromosome specific array-CGH in 199 men with different sperm count followed by the analysis of selected,
patient-specific deletions in large groups of cases and normozoospermic controls.
Results: We identified 73 CNVs, among which 55 are novel, providing the largest collection of X-linked CNVs in relation to
spermatogenesis. We found 12 patient-specific deletions with potential clinical implication. Cancer Testis Antigen gene
family members were the most frequently affected genes, and represent new genetic targets in relationship with altered
spermatogenesis. One of the most relevant findings of our study is the significantly higher global burden of deletions in
patients compared to controls due to an excessive rate of deletions/person (0.57 versus 0.21, respectively; p = 8.78561026)
and to a higher mean sequence loss/person (11.79 Kb and 8.13 Kb, respectively; p = 3.43561024).
Conclusions: By the analysis of the X chromosome at the highest resolution available to date, in a large group of subjects
with known sperm count we observed a deletion burden in relation to spermatogenic impairment and the lack of highly
recurrent deletions on the X chromosome. We identified a number of potentially important patient-specific CNVs and
candidate spermatogenesis genes, which represent novel targets for future investigations.
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Introduction
Male factor infertility affects about 7% of men in the general
population and the etiology of altered spermatogenesis remains
unknown in about 40% of cases (‘‘idiopathic infertility’’) and it is
likely that a large proportion of them are caused by still unknown
genetic factors [1]. Nevertheless, besides abnormal karyotype and
Y chromosome microdeletions no other recurrent genetic anom-
alies have been identified in men with primary testicular failure,
raising questions about the appropriateness of the investigative
approaches used so far [2–4]. The first innovative study applying
whole-genome analysis of SNPs and the successive follow-up study
failed in leading to the identification of recurrent genetic factors
with large effect size [5,6]. Recently, high resolution array
Comparative Genomic Hybridisation (array-CGH) studies identi-
fied new spermatogenesis candidate genes on autosomes and on
the X chromosome and some recurring and private patient-
specific CNVs with potential clinical interest [7,8].
Both sex chromosomes are enriched with genes prevalently or
exclusively expressed in the testis [9,10]. Nevertheless, only Y
chromosome-linked Copy Number Variants (CNVs) and Y-linked
genes have been demonstrated as important contributors to
impaired sperm production in humans [for review see [11,12]). In
particular, the so called AZoospermia Factor (AZF) regions on the
Yq have been found deleted in about 5–10% of azoospermic men
(absence of spermatozoa in the ejaculate) and 2–5% of severe
oligozoospermic men (,5 millions spermatozoa in the ejaculate).
Data on the potential role of X-linked gene products in
spermatogenesis derive mainly from model organisms and a
higher than expected number of X-linked spermatogenesis genes
have been identified [10,13]. The apparent paucity of information
in humans is probably related to the scarcity of X-linked genes
studied (only eight), none of which yet described as causative,
except for the AR gene [14]. Similarly, the question whether the X
chromosome contains AZF-like regions has not been sufficiently
explored so far.
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In order to advance the understanding of the role of X-linked
CNVs and genes in male infertility, we applied an innovative
approach based on high resolution X chromosome specific array-
CGH. Given that such a detailed analysis of the X chromosome
has not been published until now and the testicular function of
subjects included in the Genomic Variant Database is unknown
(except for 30 X-linked CNVs (23 duplications and 7 deletions)
reported in the recent paper by Tuttelmann et al. [7]), ours is the
first study providing a detailed analysis of X-linked losses and gains
in several hundred subjects with known sperm parameters.
Materials and Methods
Subjects
The local Ethical Committees of the University Hospital
Careggi and the Fundacio´ Puigvert approved the study. All
participants signed an informed consent. We analyzed with array-
CGH 96 idiopathic infertile subjects with different grade of
spermatogenic impairment (49 azoospermic, 25 cryptozoospermic
and 22 oligozoospermic men) and 103 normozoospermic men.
Infertile patients were selected on the basis of a comprehensive
andrological examination including medical history, semen
analysis, scrotal ultrasound, hormone analysis, karyotype and Y
chromosome microdeletion screening. Patients with mono- or
bilateral cryptorchidism, varicocele grades 2 and 3, obstructive
azoospermia, recurrent infections, iatrogenic infertility, hypogo-
nadotrophic hypogonadism, karyotype anomalies, Y chromosome
microdeletions including partial deletions of the AZFc region, and
partial AZFc duplications and patients with non-Italian or non-
Spanish origin were excluded. Testis histology was available for 47
men. Controls in the Spanish cohort were fertile normozoospermic
men undergoing pre-vasectomy, whereas the Italian control cohort
included normozoospermic volunteers not belonging to infertile
couples (60% with proven fertility). The ethnic/geographic
composition was similar in the control and patient groups (40%
Spanish and 60% Italians).In the second part of the study, we
performed a case-control association study reaching a total of 359
patients and 370 normozoospermic controls on 13 selected CNVs
which appeared to be specific to infertile men based on the array-
CGH analysis. Detailed phenotypic data relative to the study
populations are provided in Table 1.
Methods
Germline DNA was extracted from peripheral blood samples in
all the participants with standard methods.
Array-CGH. Customized array-CGH platforms (custom
8660 K, Agilent Technologies, Santa Clara, CA, USA) were
generated using the eArray software (http://earray.chem.agilent.
com/); 53069 probes (60-mer oligonucleotides) were selected from
those available in the Agilent database and cover the whole
chromosome X, including Xp and Xq pseudoregions, with a
medium resolution of 4 Kb. Four replicate probe groups, with
every probe present in two copies on the platform, were designed
in regions containing mouse infertility-associated genes i.e. sperm
protein associated with the nucleus, X-linked family members
(SPANX); testis expressed 11 TEX11, TAF7-like RNA polymerase
II, TATA box binding protein (TBP)-associated facto (TAF7L)
and). In these regions, the medium resolution is 2 Kb. The array
also included, for the normalization of copy number changes,
Agilent control clones spread along all autosomes (6842 probes).
As a reference DNA, we used the same normozoospermic subject
for all the study population. This control DNA was already
characterized for CNV content in previous array-CGH experi-
ments against eight different normospermic controls and presented
one private gain of 27 Kb mapping to Xcentr which was not
considered for the frequency analyses. 300 ng of test DNA and
control DNA were double-digested with RsaI and AluI (Promega)
for 1 hour at 37uC. After digestion, samples were incubated at
65uC for 20 minutes to inactivate the enzymes, and then labeled
by random priming (Agilent Technologies) for 2 hours using Cy5-
dUTP for the test DNA and Cy3-dUTP (Agilent Technologies) for
the control DNA. Labeled DNAs were incubated at 65uC for
10 minutes and then purified with Microcon YM-30 filter units
(Millipore, Billerica, USA). Every purified sample was brought to a
total volume of 9.5 ml in 1xTE (pH 8.0, Promega), and yield and
specific activity were determined for each sample using a
NanoDrop ND-1000 UV-VIS Spectrophotometer (Labtech Inter-
national LTD). The appropriate cyanine 5- and cyanine 3-labeled
samples were combined in a total volume of 16 ml. After sample
denaturation and pre-annealing with 5 ul of Human Cot-1 DNA
(Invitrogen, Carlsbad, CA), hybridization was performed at 65uC
with shaking for 24 hours. After two washing steps, the array was
analyzed through the Agilent scanner and the Feature Extraction
software (v10 1.1.1). Graphical overview was obtained using the
DNA Analytics (v4.0.73). All the array experiments were analysed
using the ADM-2 algorithm at threshold 5. Aberrant signals
including 3 or more adjacent probes were considered as genomic
CNVs (Figure S1). The positions of oligomeres refer to the Human
Genome March 2006 assembly (hg18). All experimental data was
submitted to GEO repository with the following Series accession
number: GSE37948.
Molecular genetic analyses for confirmation of array-CGH
data and for the case-control study
Molecular analysis of deletions. For the first step screening
as for the confirmatory step, we performed PCR protocol in a final
volume of 10 ml containing 70 ng of genomic DNA, 3 mM
MgCl2, 400 mM deoxynucleotides triphosphates, 10 pmol of
specific primers, 50 U/ml of Taq DNA Polymerase (Promega
PCR MASTER MIX 2X). All the primers for the first step
screening had an optimal annealing temperature between 58–
60uC and suspected deletions were further confirmed by i)
lowering the annealing temperature (55uC); ii) performing
additional PCRs with alternative primers (see details in the Table
S1).
Molecular analysis of gains and the loss CNV31. Gains
and loss CNV31 screening were performed using pre-designed
TaqManH Copy Number Assays or Custom TaqManH Copy
Number Assays (Applied Biosystems). All assays were conducted
using three or four replicates for each sample (on the basis of the
assay quality), in a final volume of 20 ul according to the
manufacturer’s instructions. The reaction mix components were:
1X TaqManH Genotyping Master Mix, 1X TaqManH Copy
Number Assay, 1X TaqManH Copy Number Reference Assays,
10 ng of genomic DNA. Briefly, the TaqManH Copy Number
Assay – containing two specific primers and a FAMTM dye-
labeled MGB probe to detect the genomic DNA target sequence –
is run in duplex with the TaqManH Copy Number Reference
Assays – containing two primers and a VICH dye-labeled
TAMRATM probe to detect the genomic DNA reference
sequence. On each plate the same normozoospermic control used
as reference DNA for array-CGH experiments (calibrator sample),
the DNA sample of the CNV carrier and the No Template
Control (NTC) were run. The CopyCaller SoftwareTM was used
for post-PCR data analysis for all the copy number quantitation
experiments. Information about qPCR probes are provided in
Table S2.
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Statistical analysis
Statistical analyses were performed using the statistical package
SPSS (version 17.0.1, Chicago, IL, USA). Non-parametric Mann-
Whitney U test was performed for comparisons of: i) median
values of CNV number and DNA change between patients and
controls; ii) median values of sperm concentration and total sperm
count in relationship with CNV number. Frequencies were
compared by Fisher exact test.
Results
Characterization of X-chromosome linked CNVs
We performed a high resolution array-CGH analysis using a
microarray containing probes densely covering the complete
human X chromosome (average resolution: 4 kb). Of the 199
subjects analyzed (96 idiopathic infertile subjects and 103
normozoospermic men), 97 (36 patients and 61 controls) showed
the lack of CNVs, whereas the remaining 102 samples were found
to carry 73 CNVs (44 gains and 29 losses) (Tables 2, 3, and 4).
Thirty-two CNVs intersected genes/transcription units based on
data available in genomic databases. As shown in Figure 1, CNVs
were evenly distributed along the X chromosome with higher
density in the PAR1.
Since homologous sequences at the border of a CNV may act as
a substrate for non-allelic homologous recombination (NAHR), we
checked the nature of regions flanking (between the minimum-
maximum size of the CNV and approximately up to 1 Mb from
the maximum size) the identified CNVs in order to understand
whether NAHR is likely to occur (UCSC Genome Browser).
Highly homologous sequences were identified only in 19% of
CNVs, indicating that NAHR is not involved in the majority of
observed CNVs. This figure was concordant with other observa-
Table 1. Clinical description of the study population.
A
SPERM COUNT PATIENTS (n =359) CONTROLS (n=370)
Total sperm count (106) median (25th–75th percentile) 2.6 (0.00–13.62) 263.20 (159.00–405.50)
mean 6 SD 8.77612.72 311.796199.99
Sperm concentration (106/ml) median (25th–75th percentile) 0.90 (0.00–4.40) 76 (50.00–117.50)
mean 6 SD 2.5663.27 91.32659.64
B
GEOGRAPHIC ORIGIN SEMEN PHENOTYPE
ARRAY-CGH STUDY
(n=96)
CASE-CONTROL
STUDY (n=263)
TOTAL
(n =359)
ITALIAN (n=233) azoospermic 15 42 57
cryptozoospermic 20 17 37
oligozoospermic 22 117 139
severe oligozoospermic (,56106/ml) 17 47 -
moderate oligozoospermic(,206106/ml) 0 12 -
SPANISH (n=126) azoospermic 34 15 49
cryptozoospermic 5 36 41
oligozoospermic 0 36 36
severe oligozoospermic (,56106/ml) 0 24 -
moderate oligozoospermic(,206106/ml) 0 12 -
C
HORMONAL PARAMETERS ARRAY-CGH STUDY (n=96) CASE-CONTROL STUDY (n=263) TOTAL (n =359)
FSH (U/L)
Mean 6 SD 13.4069.09 11.13610.08 11.7469.84
Median (25th–75th percentile) 11.38 (5.30–19.0) 8.10 (4.27–14.30) 8.70 (4.40–15.0)
LH (U/L)
Mean 6 SD 5.0262.34 5.4664.02 5.3663.72
Median (25th–75th percentile) 4.45 (3.30–6.21) 4.60 (3.20–6.75) 4.60 (3.20–6.70)
TESTOSTERONE (ng/ml)
Mean 6 SD 5.1862,.94 4.4962.08 4.6462.30
Median (25th–75th percentile) 4.80 (3.51–6.40) 4.20 (3.40–5.20) 4,.20 (3.40–5.40)
TESTIS VOLUME (ml)
Mean 6 SD 11.5564.55 12.8964.32 12.5464.42
Median (25th–75th percentile) 11.50 (8.0–14.0) 13.0 (9.0–14.87) 13.0 (9.0–14.50)
A) Semen phenotype of the entire study population (array-CGH and case-control study); B) Description of all analyzed patients (array-CGH and case-control study)
according to their geographic origin and semen phenotype; C) Hormonal levels and testis volumes of all analyzed patients (array-CGH and case-control study).
doi:10.1371/journal.pone.0044887.t001
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tions reporting a similar frequency of potential NAHR targets
[15]. It is interesting to note that in some areas (Xp11.12-q21.1)
only duplications were found, whereas from Xq27.1-q27.3 only
deletions were detected. One of the PAR1-linked losses (CNV15)
was found in 23 patients and only once in controls (Figure 1b).
This small CNV has already been described in the Database of
Genomic Variants (DGV) both as loss and gain. This CNV was
situated inside a 3914 bp Simple Tandem Repeat which included
two Segmental Duplications (respectively of 1498 bp and 1444 bp)
that therefore may act as substrate for NAHR. This mechanism
may have lead also to reciprocal duplication and in fact CNV14,
identified in our study, is the reciprocal duplication of CNV15. No
genes were identified inside or nearby CNV14/15 which made it
difficult to attribute a pathogenic role to this loss. Moreover, the
same sequence was present also on the Y chromosome which
further complicated the interpretation of the results.
Considering the size of detected CNVs, which ranged from
1.4 Kb to 1609 Kb (Tables 2, 3, and 4), we noticed that losses
were typically of small/medium size and only 17% of them were
large (Figure 2). Conversely, large gains represented 48% of the
total CNVs and the difference between frequencies of losses and
gains of .100 Kb was statistically significant (p = 0,012). Small
Table 3. List of the 33 control-specific (not found in idiopathic patients) CNVs detected by array-CGH and their description
according to type, gene location (NO=no gene found within) and occurrence in the Database of Genomic Variants (DGV).
CNV type
CNV
code Region Size (Kb) Start position End position
Coding
sequences
within the CNV* DGV Frequency
LOSSES 5.B Xp22.33 12.63 701,071 713,696 NO 1
25.A Xp21.2 9.69 31,282,923 31,292,613 DMD 1
25.B Xp21.1 28.26 33,953,232 33,981,492 NO Variation_7783 2
33.A Xp11.21 58.89 56,403,390 56,462,278 NO 1
53.A Xq24 170.73 118,278,913 118,449,646 SLC25A43 1
58.A Xq25 12.68 125,198,109 125,210,792 NO 1
60.A Xq26.3 50.84 134,801,361 134,852,198 SAGE1 1
60.D Xq27.1 217.83 140,175,103 140,392,930 NO 1
66.A Xq28 37.12 147,393,583 147,430,698 AFF2 1
71.A Xq28 (PAR) 122.36 154,755,542 154,877,901 VAMP7 1
GAINS 4.A Xp22.33 (PAR) 237.08 153,373 390,452 PLCXD1 GTPBP6
PPP2R3B
1
5.A Xp22.33 (PAR) 241.98 674,222 916,206 NO 1
5.C Xp22.33 (PAR) 420.72 747,358 1,168,080 NO 1
12.A Xp22.33 (PAR) 6.61 1,693,897 1,700,511 ASMT 1
12.B Xp22.33 (PAR) 683.74 1,716,023 2,399,766 ASMT DHRSX 1
15.A Xp22.33 (PAR) 27.94 2,382,699 2,410,643 DHRSX Variation_83270 1
15.B Xp22.33/22.32 280.09 4,206,493 4,486,580 NO 1
16.A Xp22.31 1609.42 6,487,238 8,096,662 HDHD1 STS VCX
PNPLA MIR651
1
19.A Xp22.31 129.96 7,961,788 8,091,751 MIR651 Variation_9337 1
19.B Xp22.31 177.54 8,411,159 8,588,699 KAL1 1
20.A Xp22.2 665.88 14,590,604 15,256,487 GLRA2 FANCB
MOSPD2 ASB9
ASB11 PIGA
1
20.B Xp22.13 13.34 18,018,894 18,032,238 NO 1
25.C Xp21.1 185.02 34,931,807 35,116,827 NO 1
25.D Xp21.1 215.00 35,269,628 35,484,626 NO 1
31.A Xp11.23 78.87 48,021,982 48,100,848 SSX3 1
34.A Xp11.12 48.06 56,870,427 56,918,489 NO 1
36.A Xq11 716.03 63,925,948 64,641,977 ZC4H2 ZC3H12B 1
38.A Xq13.2 192.04 74,375,875 74,567,915 UPRT ZDHHC15 Variation_74012 1
38.B Xq13.3 153.23 75,123,387 75,276,621 NO 1
55.A Xq25 53.80 120,385,787 120,439,584 NO 1
59.A Xq26.3 24.69 134,151,039 134,175,725 NO 1
60.B Xq26.3 13.45 136,050,422 136,063,872 NO 1
60.C Xq26.3 91.26 137,089,527 137,180,783 NO 1
*CNV minimum size.
doi:10.1371/journal.pone.0044887.t003
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CNVs (,10 Kb) were more frequently found in patients in respect
to controls whereas large gains have been found mainly in controls
(Figure 2).
According to the Database of Genomic Variants (DGV)
website, losses/gains were divided into ‘‘known’’ and ‘‘novel’’,
identifying 21 novel losses and 34 novel gains (Tables 2, 3, and 4).
Among the 73 CNVs, 31 (15 losses and 16 gains) were found only
in patients, ‘‘patient-specific’’ (Table 2) and 33 (10 losses and 23
gains) were found only in the control group, ‘‘control-specific’’
(Table 3). Of the remaining 9 CNVs, only one gain (CNV12) was
found more frequently among controls whereas those resulting
more frequent among patients (‘‘patient-enriched’’) were deletions.
The rest (4 gains and 1 deletion) were found to equally occur in
both patients and controls (Table 4). These data suggest that gains
are less likely to affect spermatogenesis since 63% of them (28/44)
were found also in normozoospermic controls. On the contrary,
deletions were less frequent in controls (11/29; 38%) indicating
that in the presence of a deletion an abnormal sperm phenotype is
more likely to occur. A general outline of the array-CGH findings
with phenotypic description is provided in Table S3.
CNV burden
In order to assess the potential impact of CNVs in cases versus
controls, we used two primary measures of CNV burden: the
mean size and the mean number of CNVs/individual (Table 5A).
The mean value of losses bp was significantly higher in patients
than in controls (11.79 Kb and 8.13 Kb, respectively;
p = 3.43561024). All losses were confirmed by PCR plus/minus
or Real Time PCR, except for PAR-linked losses (n = 4), for which
no suitable assay could be designed. The number of CNVs/person
was significantly higher in patients compared to controls
(p = 0.002) and depended on the overrepresentation of losses in
the former group (0.57 versus 0.21; p= 8.78561026) (Table 5).
CNV15, the most frequently found loss appears to be the major
contributor to the deletion burden, however even without this loss
the number of losses/person is significantly higher in the patient’s
group (p = 0.041). Phenotypic description of patients (loss-carriers
and no CNV-carriers) is provided in Table S4. Although the
frequency of patients with more than one CNV (n= 19; 19.8%)
was nearly twice that of controls (n = 11; 10.7%), the difference did
not reach statistical significance (p= 0.078). On the other hand,
comparing the frequencies of subjects with $1 CNV in cases
versus controls, we observed a highly significant difference when
considering the total number of CNVs (p = 0.003) and of losses
(p,0.001) (Table 5B).
CNVs and semen parameters
A significant association with sperm concentration and total
sperm number was observed among patients when considering the
total CNV number (Table 6). Patients with more than 1 CNV had
a significantly lower sperm concentration and total sperm count
than those with #1 CNV (0.260.66106/ml versus 1.062.06106/
ml; p,0.022; 2.364.66106 versus 1.063.36106; p,0.032). The
maximum number of CNVs/subject was three, and of the five
patients with three CNVs four were azoospermic and one was
severely oligozoospermic with ,1 million spermatozoa/ejaculate
(Table S6). All of them had at least one private CNV (uniquely
found in this patient), and only one patient (07-170) shared two
recurrent CNVs with two others (07-13, 07-30). Given that the
selection of patients was based on the absence of known causes of
spermatogenetic failure, subjects with multiple CNVs did not show
any additional andrological anomaly or other relevant diseases.
Semen parameters and testis histology of patients and controls
with .1 CNVs are reported in Table S5, 6.
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Screening for selected deletions
To further investigate the potential clinical implications of
losses, 13 patient-specific deletions were subsequently screened in a
large group of infertile and normozoospermic men: excluding
CNV66, they all remained patient-specific (Table 7). Due to the
rarity of the 12 patient-specific losses, statistically significant
Figure 1. Schematic representation of the distribution of the 73 CNVs (44 gains and 29 losses) along the X chromosome identified
by high resolution X chromosome specific array-CGH analysis. A) The histogram shows that the 73 CNVs were evenly distributed along the X
chromosome but displayed a higher density in the pseudoautosomal region 1, PAR1 (Xp22.33). B) The frequency of gains (upwards) and losses
(downwards) per X chromosome region in patients and controls are indicated.
doi:10.1371/journal.pone.0044887.g001
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differences were not observed in their frequencies compared to the
control group. In fact, 8/12 were private (found in a single
individual) whereas only 4 were recurrent with a still relatively low
frequency (0.5–1.1%).
Recurrent patient-specific CNVs. Among the patient-
specific recurrent CNVs, three deletions are of major interest.
CNV67, observed in 1.1% of patients may remove (considering its
maximum size) the melanoma antigen family A, 9B (MAGEA9B),
which belongs to the Cancer Testis Antigens (CTAs) gene family,
Figure 2. Array-CGH study.: distribution of the 73 CNVs according to their size: small (,10 Kb), medium (10–100 Kb) and large (.100 Kb) referred
to A) all CNVs (44 gains and 29 losses); B) losses; C) gains. Losses were typically of small/medium size (52%) whereas gains are generally of larger size
(48%). On the side, tables display the number of A) all CNVs; B) losses; C) gains of different size and categorized according to their occurrence in
patients/controls: i) ‘‘patient-specific’’ when found only in patients; ii) ‘‘control-specific’’ when found only in controls; iii) ‘‘patient-enriched’’ when
found predominantly in patients; iv) ‘‘control- enriched’’ when found predominantly in controls; v) ‘‘common’’ when found at a similar frequency in
patients and controls.
doi:10.1371/journal.pone.0044887.g002
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expressed exclusively in the testis with the highest expression level
in spermatocytes and in some tumour cell lines [16]. This deletion
may also affect additional genes with prevalent or exclusive
expression in the testis such as other CTAs and the following:
transmembrane protein 185A (TMEM185A), chromosome X open
reading frame 40A (CXorf40A), X linked heat shock transcription
factor family (HSFX) all situated at ,1 Mb from the deletion.
Phenotypes of patients with this deletion ranged from azoospermia
due to Sertoli Cell Only Syndrome (SCOS, [17]) to oligozoos-
permia. CNV 31 presents a reciprocal duplication (CNV30,
Table 2) and was observed in 4 patients (two found by array-GH
and two by qPCR) and 0/325 controls. CNVs 30/31 affect the
dosage of zinc finger protein 630 (ZNF630), a gene with unknown
function; however, considering their maximum extension, addi-
tional genes with exclusive expression in the testis such as the
sperm acrosome associated 5 SPACA5,/SPACA5b) are also
involved. CNV32 does not remove any gene directly, but it is
situated within an area abundant in CTA genes. In order to define
whether the underlying mechanism of these deletions is NAHR we
analyzed the flanking regions. Only CNV 30/31 showed
Segmental Duplications (SD) which may explain the recurrence
of deletion/duplication events. Although also CNV67 was found
in 4 patients, this deletion does not have a reciprocal duplication
and it is not flanked by SDs. An alternative mechanism for the
formation of CNV67 could be Non Homologous End Joining
(NHEJ), since substrates for this mechanism are highly represented
in this area (many LINE and Alu elements). However this
hypothesis requires further confirmation by the fine mapping of
the breakpoints.
Private patient-specific CNVs. Concerning private patient-
specific deletions, which were found only in single patients, we
observed two deletions directly affecting gene dosage. CNV50
removes the ARMCX5-GPRASP2 read-through (ARMCX5-
GPRASP2) genes for which no testis expression data are available.
The carrier of this deletion suffers from azoospermia due to
SCOS. CNV61, observed in one azoospermic man, removes
another CTA family member, the melanoma antigen family C, 3
MAGEC3. This deletion may also affect other neighbouring CTA
genes, such as the melanoma antigen family C, 1 MAGEC1 and
Sperm protein associated with the nucleus, X-linked, family
Table 5. Array-CGH study: Comparison between patients and controls of the mean number and mean extension of CNVs (A) as
well as the number of all subjects bearing more than one CNV (B).
A PATIENTS (n =96) CONTROLS (n=103) p
Mean CNV
number ± sd
Mean CNV extension
(Kb) ± sd
Mean CNV
number ± sd
Mean CNV extension
(Kb) ± sd p1 p2
LOSSES+GAINS 0.8760.85 36.21685.4 0.5460.76 73.876222.08 2.09561023 0.113
LOSSES 0.5760.64 11.79638.43 0.2160.46 8.13632.30 8.7856106 3.43561024
GAINS 0.3060.54 24.42676.50 0.3360.62 65.746220.07 0.862 0.733
B PATIENTS (n=96) CONTROLS (n=103) p OR (95% CI)
$1 CNV/subject 60 42 0.003 1.5 (1.2–2.0)
$1 loss/subject 47 20 ,0.001 2.5 (1.6–3.9)
$1 gain/subject 25 28 0.874 -
sd = standard deviation. OR =odds ratio. CI = confidence interval. p1 refers to the mean number of CNV/subject. p2 refers to the mean DNA change/subject.
doi:10.1371/journal.pone.0044887.t005
Table 6. Array-CGH study: comparison of patients’ semen parameters according to the number of CNVs.
PATIENTS (n=96)
SPERM CONCENTRATION (n6106/ml) p TOTAL SPERM NUMBER (n6106) p
0 CNV (n=36) 1.262.4 (0.01; 0.0–12.0) 2.965.7 (0.01; 0.0–30)
$1 CNV (n=60) 0.661.3 (0.0; 0.0–6.2) 0.068 1.663.4 (0.0; 0.0–17.4) 0.075
0 LOSS (n=49) 1.062.1 (0.01; 0.0–12.0) 2.765.0 (0.01; 0.0–30.0)
$1 LOSS (n =47) 0.661.5 (0.0; 0.0–6.2) 0.053 1.463.6 (0.0; 0.0–17.4) 0.051
0 GAIN (n =71) 1.062.1 (0.0; 0.0–12.0) 2.464.9 (0.0; 0.0–30.0)
$1 GAIN (n =25) 0.460.7 (0.0; 0.0–2.3) 0.185 1.362.3 (0.0; 0.0–6.4) 0.215
#1 CNV (n=77) 1.062.0 (0.0; 0.0–12.0) 2.364.6 (0.0; 0.0–30.0)
.1 CNV (n=19) 0.260.6 (0.0; 0.0–2.0) 0.022 1.063.3 (0.0; 0.0–13.4) 0.032
#1 LOSS (n =88) 0.961.9 (0.0; 0.0–12.0) 2.164.4 (0.0; 0.0–30.0)
.1 LOSS (n =8) 0.260.6 (0.0; 0.0–1.8) 0.230 1.764.7 (0.0; 0.0–13.4) 0.309
#1 GAIN (n =92) 0.861.9 (0.0; 0.0–12.0) 2.264.5 (0.0; 0.0–30.0)
.1 GAIN (n =4) 0.060.0 (0.0; 0.0–0.01) 0.293 0.060.0 (0.0; 0.0–0.01) 0.29
Sperm concentration and total sperm number are expressed as: mean 6 standard deviation (median; range). Significance is depicted by a p value,0.05.
doi:10.1371/journal.pone.0044887.t006
X Chromosome Deletions and Male Infertility
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member E (SPANXE). Four deletions (CNV22, 54, 56 and 57)
contained several (from 4–32) conserved transcription factor
binding sites, but the neighbouring genes were relatively distant
(from 8 Kb to 400 Kb).
Discussion
The diffusion of assisted reproductive techniques as a thera-
peutic option in severe male factor infertility raised several
questions about the short and long-term consequences on the
offspring, since infertile men are at higher risk of being carriers of
genetic anomalies in both their genomic DNA and gametes.
Although the importance of diagnosing genetic factors in this
category of future fathers is fully recognized, the diagnostic workup
of infertile men is still limited to a few genetic tests. Our working
hypothesis was that, similarly to Y chromosome-linked CNVs
(AZF and gr/gr deletions), we would be able to identify recurrent,
pathogenic deletions on the X chromosome. First, an X-
chromosome specific high resolution array-CGH analysis was
carried out in 199 men with known sperm count and was followed
by a screening of selected CNVs in several hundred infertile
patients and normozoospermic controls. Our array-CGH analysis
showed that 50% of subjects presented at least one CNV, and the
majority of these CNVs (55/73) were not reported in currently
available databases of genomic variants. Among the few X-linked
CNVs reported in subjects with known sperm count [7] only six
partially or completely overlapping CNVs were found. This can be
due to both technical issues (different array resolution, different
criteria used for the interpretation of data, lack of validation in the
Tuttelmann paper) and/or due to the patient selection criteria
(azoospermic men were selected for a specific histology, called
SCOS, in the Tuttelmann et al paper [7]). Interestingly, a small
deletion, CNV 69 on Xq28 was observed in 7 patients and 3
controls and it maps inside a CNV reported by Tuttelmann et al
[7] as patient-specific, present in a single oligozoospermic German
man (‘‘private’’). This discrepancy is likely due to the larger size
(34 Kb) of the patient-specific deletion in the German patient
compared to our 10 subjects (11.7 kb). On the contrary, a
reciprocal deletion/duplication (CNV31/CNV30) was observed
exclusively in patients (n = 4) in our study, whereas Tuttelmann et
al. found two normozoospermic carriers of the duplication and
one carrying the deletion [7]. However, the deletion encountered
in the above German study was 25 Kb smaller than CNV31/30.
An other interesting finding concerns two partially overlapping
gains detected in both studies, which affect the dosage of two genes
(H2BFWT and H2BFM). In our study this CNV (CN51) has been
found both in controls (n = 4) and patients (n = 5), whereas in the
German study [7] it was found only in an oligozoospermic patient.
Given that the larger CNV reported in the German study [7]
duplicates also two other genes (TMSB15B, H2BFXP), the
combined analysis of the results suggests that it is more likely
that the not shared genes, situated in the larger duplication, are
responsible for the observed oligozoospermic phenotype.
The further analysis of patient-specific deletions (n = 13)
revealed that .90% of them are unique or rare (frequency
,1%). These data are in line with the previous whole genome
array-CGH study [7] in which among the 27 patient-specific
CNVs only one recurrent duplication was found in two
oligozoospermic men. Similarly in the paper by Stouffs et al,
among the 10 patient specific autosomal CNVs only two were
recurrent [8]. The role of rare CNVs has already been established
for other multifactorial diseases [18,19] and since mutations
causing spermatogenic failure are unlikely transmitted to the next
generation, we can predict that de novo mutations probably play a
major role in primary testicular failure. It remains difficult to
ascertain the importance of rare patient-specific CNVs in
spermatogenesis through family analysis, since analysis on
maternal X-chromosome would not be informative and brothers
(with a 50% chance of sharing the same X chromosome) were not
available for analysis. The difficulty to obtain DNA from relatives
in relationship with infertility studies is related to the delicate
nature of this condition and for this reason the two previous array-
CGH studies were also unable to define the de novo nature of the
identified CNVs. As an alternative way to explore their potential
clinical relevance, we performed a search for functional genomic
regions (protein coding genes, microRNAs, conserved transcrip-
tion binding sites) mapping inside or nearby the 13 deletions of
interest. Since men are hemizygous for X-linked genes, their
CNV-dependent altered expression cannot be compensated by a
normal allele and could potentially lead to a direct pathological
effect. Ours is the first study suggesting that X-linked CTA family
members are recurrently affected and their dosage variation may
play a role in CNV-related spermatogenic failure. CTA genes
comprise more than 240 members from 70 families and are
generally divided into two broad categories: X-linked (mostly
multicopy genes) and non-X CTA genes (mainly single copy genes
located on autosomes) [for review see [16,20]]. These genes are
normally expressed only in germ cells but aberrant activation has
also been reported in a number of malignant tumors. The
exclusive physiological expression in germ cells strongly suggests a
role in spermatogenesis hence human CTA gene family members
are largely unexplored and no clinical data is available.
Interestingly, by tracing the evolutionary history of CTA genes,
it has been demonstrated that CTA genes in general and the X
chromosome linked CTA genes in particular are under strong
diversifying pressure and amongst the fastest-evolving genes in the
human genome [21]. Consequently, many of the human X-linked
CTA genes do not have easily identifiable orthologues in the
mouse or rat genomes, which makes it difficult to study the role of
these genes in animal models. Clues regarding functionality of
CTAs for many of these proteins point to a role in cell cycle
regulation or transcriptional control [for review see [22]]. Data
obtained in the 103 controls (array-CGH analysis) indicates that in
this group only one control-specific deletion contained a CTA
gene, the sarcoma antigen 1 SAGE1, which indicates that this gene
is unlikely a spermatogenesis candidate gene. In support of such a
statement, the expression of this gene is extremely low in the testis.
On the contrary, for the patient-related CTA genes expression
levels in the testis and germ cells were substantially higher. Apart
from CTA family members we identified other potential candidate
genes in the patient group which deserve further genetic screening.
On the contrary, we can conclude that those genes which are
deleted in control subjects, are unlikely to be spermatogenesis
candidate genes since their absence is compatible with normal
spermatogenesis. Among the 6 gene-containing control–specific
losses, with the exception of vesicle-associated membrane protein 7
(VAMP7), the level of testicular expression is either absent or very
low. VAMP7 is situated in PAR2 and it has been described as
strongly expressed in the testis, especially in spermatids. Our data
indicates that VAMP7 haploinsufficiency (i.e. one copy of the gene
is still retained on the Y-linked PAR2) does not impair
spermatogenesis.
One of the most stimulating findings of our article is related to
the CNV burden observed in the patients’ group in relationship
with loss of genetic material. The relatively high frequency of Y
chromosome deletions (4–7% in severe spermatogenic failure)
already suggested that infertile men are more prone to the loss of
genetic material [11]. The mechanism by which Y chromosome
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deletions lead to spermatogenetic failure is not fully clarified and
they may act either by removing genes involved in spermatogen-
esis or by affecting meiosis. Here we found an excess of X-linked
CNV number and DNA loss in patients with reduced sperm
count, which was only partially related to direct gene removal,
hence the majority of deletions mapped close to gene-rich areas.
We also found a significant association between CNV number and
sperm count in the infertile group, which further reinforces the
potential link between deletion burden and spermatogenic failure.
Similarly to our data, in the paper by Tuttelmann et al [7] a
significant inverse correlation has been found between sperm
count and CNV number at the whole genome level.
Whether the observed deletions are directly responsible for the
phenotype (either affecting gene expression or interfering with sex
chromosome pairing for those mapping to the PAR regions) or
simply arise due to increased genomic instability, remains a
puzzling question. Some previous observations suggest a possible
relationship between genomic instability and male infertility and
are related to microsatellite instability [23] as well as to the
presence of multiple CNVs on the Y chromosome in men with
AZF deletions [24] and an excessive CNV number in azoospermic
men with SCOS [7]. Previously, we also observed a significant
effect of multiple rearrangements in the AZFc region on sperm
production, suggesting a potential link between a less stable
genome and spermatogenic efficiency [25]. Additionally, epide-
miological observations showing a higher incidence of morbidity
(including cancer) and lower life expectancy [22,26] in infertile
men would support a potential link between altered spermatogenic
function and genomic instability. Our study suggests a potential
involvement of increased X-linked deletion burden in the aetiology
of impaired spermatogenesis and stimulates further research to
better define its implication in primary testicular failure and on
general health issues for both the patient and his future offspring.
In conclusion, by the analysis of the X chromosome, at the
highest resolution available to date, in a large group of subjects
with known sperm count we were able to provide evidence about
the lack of highly recurrent deletions, which suggest that an AZFc-
like region does not exist on this sex chromosome. Our
investigation gives an important contribution both to the field of
genetics and reproductive medicine since we identified a large
number of novel CNVs, and by our second step analysis, we
confirmed 12 deletions as being specific to men with impaired
spermatogenesis. The analysis of gene-containing CNVs in
patients and in controls allows to discern between those that
merit future research and those which are unlikely to be involved
in spermatogenesis.
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